Please use this identifier to cite or link to this item:
Title: Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma
Authors: Chow, P.K.H. 
Poon, D.Y.H.
Khin, M.-W.
Singh, H.
Han, H.-S.
Goh, A.S.W.
Choo, S.-P.
Lai, H.-K.
Lo, R.H.G.
Tay, K.-H.
Lim, T.-G.
Gandhi, M.
Tan, S.-B. 
Soo, K.-C. 
Issue Date: 10-Mar-2014
Citation: Chow, P.K.H., Poon, D.Y.H., Khin, M.-W., Singh, H., Han, H.-S., Goh, A.S.W., Choo, S.-P., Lai, H.-K., Lo, R.H.G., Tay, K.-H., Lim, T.-G., Gandhi, M., Tan, S.-B., Soo, K.-C. (2014-03-10). Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS ONE 9 (3) : -. ScholarBank@NUS Repository.
Abstract: Background: The safety and tolerability of sequential radioembolization- sorafenib therapy is unknown. An open-label, single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable to curative therapies. Methods: Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (90Y) resin microspheres given as a single procedure. The primary endpoints were safety and tolerability and best overall response rate (ORR) using RECIST v1.0.Secondary endpoints included: disease control rate (complete [CR] plus partial responses [PR] and stable disease [SD]) and overall survival (OS). Results: Twenty-nine patients with Barcelona Clinic Liver Cancer (BCLC) stage B (38%) or C (62%) HCC received a median of 3.0 GBq (interquartile range, 1.0) 90Y-microspheres followed by sorafenib (median dose/day, 600.0 mg; median duration, 4.1 months). Twenty eight patients experienced ≥1 toxicity; 15 (52%) grade ≥3. Best ORR was 25%, including 2 (7%) CR and 5 (18%) PR, and 15 (54%) SD. Disease control was 100% and 65% in BCLC stage B and C, respectively. Two patients (7%) had sufficient response to enable radical therapy. Median survivals for BCLC stage B and C were 20.3 and 8.6 months, respectively. Conclusions: This study shows the potential efficacy and manageable toxicity of sequential radioembolization- sorafenib. Trial Registration: NCT00712790. © 2014 Chow et al.
Source Title: PLoS ONE
ISSN: 19326203
DOI: 10.1371/journal.pone.0090909
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2014-multicenter_phase_II_study_of_sequential-published.PDF631.4 kBAdobe PDF




checked on May 17, 2022


checked on May 17, 2022

Page view(s)

checked on May 12, 2022


checked on May 12, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.